Wellgistics Health to Distribute Tollo Health GLP-1 Companion Muscle Loss Medical Food to Pharmacies & Physicians

Rhea-AI Summary

Wellgistics Health (NASDAQ:WGRX) expanded distribution with Tollo Health to offer a branded GLP-1 companion muscle-loss medical food to its 6,500+ independent pharmacy network and physicians, positioned as an adjunct to GLP-1 therapies to mitigate muscle loss during and after treatment.

The company also added 3CL protease inhibitor Tollovid® to its galectin 1 & 3 inhibitor medical food Galectovid™, creating a natural antiviral combination aimed at Long COVID. The release cites a GLP-1 muscle-loss market of $53B today and an expected $156B by 2030.

Positive

• Distribution to 6,500+ independent pharmacy network
• Targets GLP-1 muscle-loss market sized at $53B today
• Positions offering for market growth to $156B by 2030
• Added Tollovid® to Galectovid™ for combined Long COVID antiviral approach
• Claims clinical data showing mitigation of sarcopenia and increased muscle mass/strength

Negative

• None.

Insights

Commercial Strategy Expert

Distribution to 6,500+ pharmacies and physicians establishes commercial reach for a novel GLP-1 adjutant.

Wellgistics expanded a distribution agreement to offer a branded medical food for GLP-1 associated muscle loss into a >6,500 independent pharmacy network and physicians. This creates direct retail and prescriber channels for a product claimed to address sarcopenia in patients on GLP-1 therapies.

The commercial outcome depends on uptake by pharmacies and clinician recommendations, formulary placement, payer acceptance, and unit economics at the pharmacy level. Adoption will hinge on clear clinical labeling, reimbursement pathways, and point-of-care education for prescribers and pharmacists.

Watch near-term metrics: rollout adoption across the Pharmacy Network, initial order volumes, and any stated reimbursement or coding pathway within the next 3–12 months; also monitor any claims substantiation or clinical endpoints the company cites in materials.

Clinical & Regulatory Expert

Company positions a clinically studied formulation as a GLP-1 adjunct and pairs two natural antiviral products for Long COVID.

The announcement cites prior clinical study data for the sarcopenia formulation and introduces Tollovid® alongside Galectovid™ as a combined natural antiviral approach targeting SARS-CoV-2 mechanisms. The statements frame the products as medical foods and supplements rather than new drugs.

Regulatory risk centers on medical food and supplement labeling rules and on making clinical claims; distribution to pharmacies and physicians does not change regulatory status. Key items to watch: any regulatory correspondence, specific clinical endpoint data the company publishes, and whether payers or professional bodies accept the medical food designation.

Monitor disclosures of the cited clinical results, any clinical endpoints claimed for muscle mass or strength, and any regulatory clarifications in the coming quarters to validate stated benefits.

• Company to offer the first clinically validated dietary management of sarcopenia, now available for GLP-1 muscle loss, positioning Wellgistics to help 6,500+ independent pharmacy network ('Pharmacy Network') and telehealth partners mitigate patient muscle loss in the GLP-1 drug market, estimated to grow to $150 billion by 2030

• Company to offer first SARS-CoV-2 related natural antiviral combo for Long COVID with addition of 3CL protease inhibitor supplement Tollovid^® to Galectovid 1 & 3 inhibitor Medical Food Galectovid^® distribution agreement to Pharmacy Network & physicians

TAMPA, FLORIDA / ACCESS Newswire / November 14, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a leader in the integration of physical and technology healthcare infrastructure for prescription drugs, today announced that it has expanded its agreement with Tollo Health to offer the first GLP-1 companion muscle loss medical food to its 6,500+ independent pharmacy network ('Pharmacy Network') and physicians. The product is a branded version of a proprietary formulation that has been widely studied in metabolic dysfunction, with patients presenting diabetes type 2, heart failure, and COPD. Wellgistics will be selling the medical food as an adjunct to GLP-1 therapies to help mitigate muscle loss during weight loss while on therapy and to mitigate weight after discontinuation.

"With the GLP-1 muscle loss market sitting at $53 billion annually according to Grandview Research and expected to reach $156 billion by 2030, driven by increase in numbers of patients and availability of oral formulation, the key side effect described by patients is outsized muscle loss," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. "By bringing to market a medical food alternative with significant clinical data in mitigating sarcopenia, even increasing muscle mass and strength, we are first to market with a data-driven, proprietary formulation that can potentially help patients more safely take this class of medication. We believe there is significant interest in a product to preserve muscle mass and increase strength as an pharmacy and/or physician recommend adjunct to prescription GLP-1 medications."

Concurrent with this announcement, the Company announced that it has expanded its antiviral offering by adding 3CL protease inhibitor product Tollovid^® to its already marketed galectin 1 & 3 inhibitor medical food Galectovid^™ primarily targeting patients with Long COVID. Tollovid combined with Galectovid represent the first natural antiviral combination available in the market targeting SARS-CoV-2 specific replication and immune function mechanisms.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.

For more information, visit www.wellgisticshealth.com.

About Tollo Health, LLC

Tollo Health, LLC is a medical foods and precision neutraceutical company seeking to bring to market proprietary formulations for the dietary management of GLP-1 treatment-related side effects and chronic viral conditions, include Long COVID. Tollo intends to bring to market a full suite of products that provide patients with prescription medication-enabling benefits in areas with approved drugs and functional relief in conditions for which there are no approved drugs, but mechanistic understanding of the disease is improving. By using tailored natural product formulation that deliver the cGMP-manufactured ingredients with the right formulation at the right dose, Tollo aims to fill a key gap in the delivery of prescription drugs that have side effects and chronic conditions for which there are no approved treatments. For more information, please visit Tollo's website at www.tollohealth.com.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

Investor Relations Contact

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Wellgistics (WGRX) announce on November 14, 2025?

Wellgistics expanded distribution to its 6,500+ pharmacy network to offer a GLP-1 companion muscle-loss medical food and added Tollovid® to Galectovid™ for Long COVID.

How large is the GLP-1 muscle-loss market Wellgistics (WGRX) is targeting?

The company cites a current market of $53 billion and an expected $156 billion by 2030.

What is the role of the medical food Wellgistics (WGRX) will distribute for GLP-1 patients?

The product is marketed as an adjunct to GLP-1 therapies to mitigate muscle loss during weight loss and after therapy discontinuation.

Which pharmacies and clinicians can access Wellgistics’ (WGRX) new GLP-1 companion product?

The product will be offered to Wellgistics’ network of 6,500+ independent pharmacies and affiliated physicians.

What combination did Wellgistics (WGRX) add for Long COVID treatment?

Wellgistics added the 3CL protease inhibitor Tollovid® to its galectin 1 & 3 inhibitor medical food Galectovid™, forming a natural antiviral combo.

Does Wellgistics (WGRX) claim clinical evidence for the muscle-loss product?

The company states the branded formulation has significant clinical data showing mitigation of sarcopenia and improvements in muscle mass and strength.